NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.23
−5.11%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.29
From 52W high−43.54%
Volume4.41M
Market cap$284.04M
P/E (TTM)—
P/S (TTM)669.9x
Div yield—
Key dataNov 4, 2026
Open
$2.29
From 52W high
−43.54%
Volume
4.41M
Market cap
$284.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
P/E (TTM)
—
RSI (14)
48.5
MomentumView details →
1D Return
−5.11%
YTD Return
+11.54%
SummaryUpdated Sep 1, 2026
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) is a development-stage life sciences company founded in 2016 and headquartered in Seattle, Washington. The company went public in August 2020 and is focused on developing revolutionary proteomics technology to unlock the complexity of the human proteome - the complete set of proteins produced by an organism. Nautilus is creating a platform that promises to dramatically advance protein analysis capabilities, potentially transforming how researchers study diseases, develop drugs, and understand biological processes at the molecular level.
Similar companies
Latest newsMore news →
Nautilus Biotechnology reported third-quarter 2026 revenue of $234,000 and a net loss of $15.636 million, or $0.12 per diluted share.7d agoNautilus Biotechnology, Inc. mutually terminated its prior at-the-market equity offering program with TD Securities (USA), LLC as sales agent.54d agoNautilus Biotechnology, Inc. entered into a sales agreement to sell up to $125,000,000 of common stock through an at-the-market offering program, with TD Securities (USA), LLC acting as sales agent.54d ago